-
Mashup Score: 1
In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his SOHO 2022 presentation as well as the other acute lymphoblastic leukemia discussions presented during the session.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML #leusm @SocietyofHemOnc #SOHO2022 https://t.co/r1t7T4bSMf
-
-
Mashup Score: 1Potential of Menin Inhibitors Is Focus of AML Session - 2 year(s) ago
AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Menin inhibitors are showing improvements in overall response by patients with relapsed/refractory #AML, said Eytan M. Stein, MD. #leusm #SOHO2022 | @MSKCancerCenter https://t.co/ChR2P0nh6X
-
-
Mashup Score: 0Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma? - 2 year(s) ago
Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out the top stories from #SOHO2022 with research from @szusmani @MSKCancerCenter @MDAndersonNews @OrcaBio @GCC_Cortes @cityofhope & more! 1. https://t.co/A9b3O5OArw 2. https://t.co/UjDeUZ6TFm 3. https://t.co/tGwpMBdTJo 4. https://t.co/QJumqcRZLC 5. https://t.co/dmi0BbtEGH https://t.co/8gH98HkZYR
-
-
Mashup Score: 0Cortes Discusses Changing Landscape of Hematology and Challenges to the Cancer Center of Today - 2 year(s) ago
The landscape of treating patients with hematologic malignancies has changed greatly throughout the career of Jorge E. Cortes, MD. Once excitement might have centered around a handful of drugs, but now there is a much more robust variety of options.Cortes, director of the Georgia Cancer Center at Augusta University, has seen the expansion of treatment for patients with hematologic malignancies….
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The landscape of treating patients with hematologic malignancies has changed greatly throughout the career of @GCC_Cortes. Once excitement might have centered around a handful of drugs, but now there is a much more robust variety of options. #SOHO2022 https://t.co/9OUuXGi39F
-
-
Mashup Score: 1
As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Improved biologic insight has led to development of novel therapies including brentuximab vedotin and the checkpoint inhibitors nivolumab and pembrolizumab. #SOHO2022 #lymsm | @MSKCancerCenter https://t.co/aRFZHzmU0J
-
-
Mashup Score: 1Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL - 2 year(s) ago
Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL @DanaFarber @SocietyofHemOnc #SOHO2022 #leusm #oncology https://t.co/8qez3NmPPX
-
-
Mashup Score: 1
Interim findings from the DREAMM-6 study hint that belantamab mafodotin plus lenalidomide and dexamethasone is effective with tolerable safety in patients with relapsed or refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Belantamab mafodotin-blmf combined with lenalidomide plus dexamethasone displayed encouraging clinical activity in a small population of patients with R/R multiple myeloma. #SOHO2022 #mmsm | @SagarLonialMD @EmoryMedicine https://t.co/5nnRpQNWeo
-
-
Mashup Score: 0Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL - 2 year(s) ago
Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL @SocietyofHemOnc #SOHO2022 #lymsm https://t.co/4ve5Orjzs3
-
-
Mashup Score: 1
William Wierda, MD, PhD, will explore the emergence of small molecule–inhibitor targeted therapies.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CLL is the most common leukemia in adults in Western countries; estimates indicate more than 20,000 individuals in the United States will receive CLL diagnoses and approximately 4410 will die of CLL in 2022. #lymsm #SOHO2022 | @MDAndersonNews https://t.co/l111Bwn9Ef
-
In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his #SOHO2022 presentation as well as the other #ALL discussions presented during the session. #leusm | @Rigshospitalet https://t.co/6aShQ2fs4n https://t.co/FPJGDzOa5W